Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII

Yuko Kamata, Torayuki Okuyama, Motomichi Kosuga, Aya O'hira, Arihiko Kanaji, Kyoko Sasaki, Masao Yamada, Noriyuki Azuma

研究成果: Article査読

39 被引用数 (Scopus)


Recent advances in systemic treatments for mucopolysaccharidosis have led to therapies that improve the multiple somatic features of this disease, but the therapeutic effect on ocular manifestations such as corneal clouding is not satisfactory. Here, we administered an adenovirus expressing human β-glucuronidase (AxCAhGUS) into the anterior chamber or intrastromal region of the cornea in mice with mucopolysaccharidosis type VII (B6/MPSVII), and successfully treated corneal clouding of MPSVII. When we injected AxCAhGUS into the anterior chamber of the eyes, cells expressing β-glucuronidase (GUSB) were located mainly in the trabecular meshwork as well as in all corneal regions, and subsequent pathological corrections in the cornea were achieved. Widespread transgene expression was also observed when we administered AxCAhGUS inside the cornea after lamellar keratotomy, and rapid elimination of the lysosomal storage in the corneal keratocytes occurred. Furthermore, intrastromal vector administration did not generate significant levels of anti-adenovirus neutralizing antibodies, and secondary vector administration was effective. Based on these observations, we conclude that it is worth developing a treatment strategy for corneal clouding in mucopolysaccharidosis based on direct intraocular administration of adenoviral vectors.

ジャーナルMolecular Therapy
出版ステータスPublished - 2001

ASJC Scopus subject areas

  • 分子医療
  • 分子生物学
  • 遺伝学
  • 薬理学
  • 創薬


「Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。